Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule (188)Re-ZHER2:41071

HER2-targeted radionuclide therapy might be helpful for the treatment of breast, gastric, and ovarian cancers which have developed resistance to antibody and antibody-drug conjugate-based therapies despite preserved high HER2-expression. Affibody molecules are small targeting proteins based on a non...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yongsheng, Vorobyeva, Anzhelika, Orlova, Anna, Konijnenberg, Mark W., Xu, Tianqi, Bragina, Olga, Loftenius, Annika, Rosander, Erica, Frejd, Fredrik Y., Tolmachev, Vladimir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146794/
https://www.ncbi.nlm.nih.gov/pubmed/35631678
http://dx.doi.org/10.3390/pharmaceutics14051092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146794/
https://www.ncbi.nlm.nih.gov/pubmed/35631678
http://dx.doi.org/10.3390/pharmaceutics14051092

Ejemplares similares